查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1512791

药物安全检测市场，占有率，规模，趋势，产业分析报告:各类服务，产品生命週期，各类型，流程，各治疗领域，各最终用途，各地区市场区隔，2024年～2032年的预测

Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，到 2032 年，全球药物警戒市场规模预计将达到 137.5 亿美元。该研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

市场的关键驱动因素包括药物摄取量的增加、新药开发的频率、药物不良反应和药物毒性的价格上涨以及药物警戒解决方案的合约趋势增加，预计将促使该行业的成长。此外，製药业的超支、药品不良事件发生率的上升以及药品错误正在推动该行业向前发展。此外，冠状病毒大流行产生了对疫苗的迫切需求，并为行业参与者提供了许多机会。

由于将固定供应成本转化为可变成本以及按需获得独特的专业知识等优势，预计外包合约领域将在预测期内占据全球市场的主要占有率。

由于产业参与者增加了引进新药的投资，预计北美在预测期内将占据全球市场的主要占有率。此外，美国和加拿大等国家的严格监管以及先进医疗保健系统的存在，预计将为该行业的成长创造有利的机会。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第 4 章全球药物警戒市场洞察

  • 药物警戒 - 产业概况
  • 药物警戒市场动态
    • 促进因素和机会
      • 慢性病的盛行率
      • 增加药物开发投资
    • 抑制因素和课题
      • 资料管理问题
  • 大环境分析
  • 药物警戒产业的趋势
  • 新冠肺炎 (COVID-19) 影响分析

第5章 全球药物安全检测市场:各服务供应商

  • 主要调查结果
  • 简介
  • 公司内部
  • 契约外包

第6章 全球药物安全检测市场:产品生命週期

  • 主要调查结果
  • 简介
  • 前临床
  • 阶段I
  • 阶段II
  • 阶段III
  • 阶段IV

第7章 全球药物安全检测市场:各治疗领域

  • 主要调查结果
  • 简介
  • 肿瘤学
  • 神经学
  • 心臟病
  • 呼吸系统
  • 其他

第8章 全球药物安全检测市场:流程

  • 主要调查结果
  • 简介
  • 案例资料管理
  • 信号检测
  • 风险管理系统

第9章 全球药物安全检测市场:各类型

  • 主要调查结果
  • 简介
  • 自发报告
  • ADR报告的强化
  • 对象现象自发报告
  • 世代心臟事件记录器
  • 电子病历挖掘

第10章 全球药物安全检测市场:各最终用途

  • 主要调查结果
  • 简介
  • 医药品
  • 生物科技企业
  • 医疗设备厂商
  • 其他

第11章 全球药物安全检测市场:地区

  • 主要调查结果
  • 简介
    • 药物安全检测市场评估:各地区，2019-2032年
  • 北美
    • 北美:各服务供应商，2019年～2032年
    • 北美:流程，2019年～2032年
    • 北美:产品生命週期，2019～2032年
    • 北美:各类型，2019-2032年
    • 北美:各治疗领域，2019年～2032年
    • 北美:各最终用途，2019年～2032年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:各服务供应商，2019-2032年
    • 欧洲:流程，2019-2032年
    • 欧洲:产品生命週期，2019-2032
    • 欧洲:各类型，2019-2032
    • 欧洲:各治疗领域，2019年～2032年
    • 欧洲:各最终用途，2019年～2032年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
  • 亚太地区
    • 亚太地区:各服务供应商，2019-2032年
    • 亚太地区:流程，2019年～2032年
    • 亚太地区:产品生命週期，2019年～2032年
    • 亚太地区:各类型，2019-2032
    • 亚太地区:各治疗领域，2019年～2032年
    • 亚太地区:各最终用途，2019年～2032年
    • 中国
    • 印度
    • 日本
    • 马来西亚
    • 印尼
    • 韩国
  • 中东·非洲
    • 中东·非洲:各服务供应商，2019-2032年
    • 中东·非洲:流程，2019-2032年
    • 中东·非洲:产品生命週期，2019-2032
    • 中东·非洲:各类型，2019年～2032年
    • 中东·非洲:各治疗领域，2019年～2032年
    • 中东·非洲:各最终用途，2019年～2032年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
  • 南美
    • 南美:各服务供应商，2019年～2032年
    • 南美:流程，2019-2032年
    • 南美:产品生命週期，2019年～2032年
    • 南美:各类型，2019-2032年
    • 南美:各治疗领域，2019年～2032年
    • 南美:各最终用途，2019年～2032年
    • 墨西哥
    • 巴西
    • 阿根廷

第12章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第13章 企业简介

  • Accenture
  • ArisGlobal
  • BioClinica, Inc
  • Capgemini
  • Clinquest Group B.V.(Linical Americas)
  • Cognizant
  • FMD K&L
  • IBM Corporation
  • ICON Plc.
  • IQVIA
  • ITClinical
  • Laboratory Corporation of America Holdings
  • Linical Accelovance
  • PAREXEL International Corporation
  • TAKE Solutions
  • United BioSource Corporation
  • Wipro Limited
Product Code: PM2355

The global pharmacovigilance market size is expected to reach USD 13.75 Billion by 2032 according to a new study by Polaris Market Research. The report "Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers of the market include rising medication intake novel drug development frequencies, rising prices of negative drug responses and drug toxicities, as well as an expanding tendency of contracting pharmacovigilance solutions is expected to boost the industry growth. Moreover, the pharmaceutical sector's excessive expenditure, rising incidence of adverse drug events, and drug mistakes are propelling the industry forward. Furthermore, the coronavirus pandemic has produced an emergency demand for a vaccine that has offered several chances for industry participants.

The contract outsources segment is expected to hold the major shares in the global market during the forecast period due to its benefits such as transforming fixed supply costs into variables, refining on-demand contact to distinctive expertise along with other benefits.

North America is expected to hold the major share in the global market over the forecast period due to increasing investment by the industry players in introducing novel drugs. Moreover, stringent regulations along with the presence of advanced healthcare systems in countries like the U.S. and Canada are expected to create lucrative opportunities for industry growth.

Some of the major players operating in the global market are ArisGlobal, Accenture, BioClinica, Inc., United BioSource Corporation, Clinquest Group B.V. (Linical Americas), Cognizant, Capgemini, FMD K&L, IBM Corporation, IQVIA, ICON Plc., ITClinical, Linical Accelovance, PAREXEL International Corporation, Laboratory Corporation of America Holdings, TAKE Solutions, and Wipro Limited.

Polaris Market Research has segmented the pharmacovigilance market report on the basis of service provider, product life cycle, type, process flow, therapeutic area, end-use, and region:

Pharmacovigilance, Service Provider Outlook (Revenue - USD Billion, 2019-2032)

  • In-house
  • Contract Outsourcing

Pharmacovigilance, Product Life Cycle Outlook (Revenue - USD Billion, 2019-2032)

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Pharmacovigilance, Type Outlook (Revenue - USD Billion, 2019-2032)

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance, Process Flow Outlook (Revenue - USD Billion, 2019-2032)

  • Case Data Management
  • Case Logging
  • Case Data Analysis
  • Medical Reviewing & Reporting
  • Signal Detection
  • Adverse Event Logging
  • Adverse Event Analysis
  • Adverse Event Review & Reporting
  • Risk Management System
  • Risk Evaluation System
  • Risk Mitigation System

Pharmacovigilance, Therapeutic Area Outlook (Revenue - USD Billion, 2019-2032)

  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others

Pharmacovigilance, End-Use Outlook (Revenue - USD Billion, 2019-2032)

  • Pharmaceuticals
  • Biotechnology Companies
  • Medical Device Manufacturers
  • Others

Pharmacovigilance, Regional Outlook (Revenue - USD Billion, 2019-2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • Italy
  • France
  • Netherlands
  • Russia
  • Spain
  • Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • Malaysia
  • South Korea
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Middle East & Africa
  • Israel
  • Saudi Arabia
  • South Africa
  • UAE

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pharmacovigilance Market Insights

  • 4.1. Pharmacovigilance - Industry Snapshot
  • 4.2. Pharmacovigilance Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of chronic disease
      • 4.2.1.2. Increasing investment in drug development
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Issues related to data management
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Pharmacovigilance Industry Trends
  • 4.6. COVID-19 Impact Analysis

5. Global Pharmacovigilance Market, by Service Provider

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 5.3. In-house
    • 5.3.1. Global Pharmacovigilance Market, by In-house, by Region, 2019-2032 (USD Billion)
  • 5.4. Contract Outsourcing
    • 5.4.1. Global Pharmacovigilance Market, by Contract Outsourcing, by Region, 2019-2032 (USD Billion)

6. Global Pharmacovigilance Market, by Product Life Cycle

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 6.3. Pre-clinical
    • 6.3.1. Global Pharmacovigilance Market, by Pre-clinical, by Region, 2019-2032 (USD Billion)
  • 6.4. Phase I
    • 6.4.1. Global Pharmacovigilance Market, by Phase I, by Region, 2019-2032 (USD Billion)
  • 6.5. Phase II
    • 6.5.1. Global Pharmacovigilance Market, by Phase II, by Region, 2019-2032 (USD Billion)
  • 6.6. Phase III
    • 6.6.1. Global Pharmacovigilance Market, by Phase III, by Region, 2019-2032 (USD Billion)
  • 6.7. Phase IV
    • 6.7.1. Global Pharmacovigilance Market, by Phase IV, by Region, 2019-2032 (USD Billion)

7. Global Pharmacovigilance Market, by Therapeutic Area

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 7.3. Oncology
    • 7.3.1. Global Pharmacovigilance Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 7.4. Neurology
    • 7.4.1. Global Pharmacovigilance Market, by Neurology, by Region, 2019-2032 (USD Billion)
  • 7.5. Cardiology
    • 7.5.1. Global Pharmacovigilance Market, by Cardiology, by Region, 2019-2032 (USD Billion)
  • 7.6. Respiratory Systems
    • 7.6.1. Global Pharmacovigilance Market, by Respiratory Systems, by Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Other Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

8. Global Pharmacovigilance Market, by Process Flow

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 8.3. Case Data Management
    • 8.3.1. Global Pharmacovigilance Market, by Case Data Management, by Region, 2019-2032 (USD Billion)
    • 8.3.2. Case Logging
      • 8.3.2.1. Global Pharmacovigilance Market, by Case Logging, by Region, 2019-2032 (USD Billion)
    • 8.3.3. Case Data Analysis
      • 8.3.3.1. Global Pharmacovigilance Market, by Case Data Analysis, by Region, 2019-2032 (USD Billion)
    • 8.3.4. Medical Reviewing & Reporting
      • 8.3.4.1. Global Pharmacovigilance Market, by Medical Reviewing & Reporting, by Region, 2019-2032 (USD Billion)
  • 8.4. Signal Detection
    • 8.4.1. Global Pharmacovigilance Market, by Signal Detection, by Region, 2019-2032 (USD Billion)
    • 8.4.2. Adverse Event Logging
      • 8.4.2.1. Global Pharmacovigilance Market, by Adverse Event Logging, by Region, 2019-2032 (USD Billion)
    • 8.4.3. Adverse Event Analysis
      • 8.4.3.1. Global Pharmacovigilance Market, by Adverse Event Analysis, by Region, 2019-2032 (USD Billion)
    • 8.4.4. Adverse Event Review & Reporting
      • 8.4.4.1. Global Pharmacovigilance Market, by Adverse Event Review & Reporting, by Region, 2019-2032 (USD Billion)
  • 8.5. Risk Management System
    • 8.5.1. Global Pharmacovigilance Market, by Risk Management System, by Region, 2019-2032 (USD Billion)
    • 8.5.2. Risk Evaluation System
      • 8.5.2.1. Global Pharmacovigilance Market, by Risk Evaluation System, by Region, 2019-2032 (USD Billion)
    • 8.5.3. Risk Mitigation System
      • 8.5.3.1. Global Pharmacovigilance Market, by Risk Mitigation System, by Region, 2019-2032 (USD Billion)

9. Global Pharmacovigilance Market, by Type

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 9.3. Spontaneous Reporting
    • 9.3.1. Global Pharmacovigilance Market, by Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
  • 9.4. Intensified ADR Reporting
    • 9.4.1. Global Pharmacovigilance Market, by Intensified ADR Reporting, by Region, 2019-2032 (USD Billion)
  • 9.5. Targeted Spontaneous Reporting
    • 9.5.1. Global Pharmacovigilance Market, by Targeted Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
  • 9.6. Cohort Event Monitoring
    • 9.6.1. Global Pharmacovigilance Market, by Cohort Event Monitoring, by Region, 2019-2032 (USD Billion)
  • 9.7. EHR Mining
    • 9.7.1. Global Pharmacovigilance Market, by EHR Mining, by Region, 2019-2032 (USD Billion)

10. Global Pharmacovigilance Market, by End-Use

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Global Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 10.3. Pharmaceuticals
    • 10.3.1. Global Pharmacovigilance Market, by Pharmaceuticals, by Region, 2019-2032 (USD Billion)
  • 10.4. Biotechnology Companies
    • 10.4.1. Global Pharmacovigilance Market, by Biotechnology Companies, by Region, 2019-2032 (USD Billion)
  • 10.5. Medical Device Manufacturers
    • 10.5.1. Global Pharmacovigilance Market, by Medical Device Manufacturers, by Region, 2019-2032 (USD Billion)
  • 10.6. Others
    • 10.6.1. Global Other End-Uses Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

11. Global Pharmacovigilance Market, by Geography

  • 11.1. Key findings
  • 11.2. Introduction
    • 11.2.1. Pharmacovigilance Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 11.3. Pharmacovigilance Market - North America
    • 11.3.1. North America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.3.2. North America: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.3.3. North America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.3.4. North America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.3.5. North America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.3.6. North America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.3.7. Pharmacovigilance Market - U.S.
      • 11.3.7.1. U.S.: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.3.7.2. U.S.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.3.7.3. U.S.: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.3.7.4. U.S.: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.3.7.5. U.S.: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.3.7.6. U.S.: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.3.8. Pharmacovigilance Market - Canada
      • 11.3.8.1. Canada: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.3.8.2. Canada.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.3.8.3. Canada: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.3.8.4. Canada: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.3.8.5. Canada: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.3.8.6. Canada: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4. Pharmacovigilance Market - Europe
    • 11.4.1. Europe: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.2. Europe.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.3. Europe: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.4. Europe: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.5. Europe: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.6. Europe: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.7. Pharmacovigilance Market - UK
      • 11.4.7.1. UK: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.7.2. UK.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.7.3. UK: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.7.4. UK: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.7.5. UK: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.7.6. UK: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.8. Pharmacovigilance Market - France
      • 11.4.8.1. France: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.8.2. France.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.8.3. France: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.8.4. France: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.8.5. France: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.8.6. France: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.9. Pharmacovigilance Market - Germany
      • 11.4.9.1. Germany: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.9.2. Germany.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.9.3. Germany: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.9.4. Germany: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.9.5. Germany: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.9.6. Germany: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.10. Pharmacovigilance Market - Italy
      • 11.4.10.1. Italy: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.10.2. Italy.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.10.3. Italy: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.10.4. Italy: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.10.5. Italy: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.10.6. Italy: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.11. Pharmacovigilance Market - Spain
      • 11.4.11.1. Spain: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.11.2. Spain.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.11.3. Spain: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.11.4. Spain: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.11.5. Spain: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.11.6. Spain: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.12. Pharmacovigilance Market - Netherlands
      • 11.4.12.1. Netherlands: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.12.2. Netherlands.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.12.3. Netherlands: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.12.4. Netherlands: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.12.5. Netherlands: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.12.6. Netherlands: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.4.13. Pharmacovigilance Market - Russia
      • 11.4.13.1. Russia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.4.13.2. Russia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.4.13.3. Russia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.4.13.4. Russia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.4.13.5. Russia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.4.13.6. Russia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5. Pharmacovigilance Market - Asia Pacific
    • 11.5.1. Asia Pacific: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.2. Asia Pacific.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.3. Asia Pacific: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.4. Asia Pacific: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.5. Asia Pacific: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.6. Asia Pacific: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.7. Pharmacovigilance Market - China
      • 11.5.7.1. China: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.7.2. China.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.7.3. China: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.7.4. China: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.7.5. China: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.7.6. China: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.8. Pharmacovigilance Market - India
      • 11.5.8.1. India: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.8.2. India.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.8.3. India: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.8.4. India: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.8.5. India: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.8.6. India: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.9. Pharmacovigilance Market - Japan
      • 11.5.9.1. Japan: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.9.2. Japan.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.9.3. Japan: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.9.4. Japan: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.9.5. Japan: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.9.6. Japan: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.10. Pharmacovigilance Market - Malaysia
      • 11.5.10.1. Malaysia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.10.2. Malaysia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.10.3. Malaysia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.10.4. Malaysia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.10.5. Malaysia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.10.6. Malaysia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.11. Pharmacovigilance Market - Indonesia
      • 11.5.11.1. Indonesia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.11.2. Indonesia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.11.3. Indonesia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.11.4. Indonesia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.11.5. Indonesia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.11.6. Indonesia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.5.12. Pharmacovigilance Market - South Korea
      • 11.5.12.1. South Korea: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.5.12.2. South Korea.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.5.12.3. South Korea: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.5.12.4. South Korea: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.5.12.5. South Korea: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.5.12.6. South Korea: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.6. Pharmacovigilance Market - Middle East & Africa
    • 11.6.1. Middle East & Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.6.2. Middle East & Africa: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.6.3. Middle East & Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.6.4. Middle East & Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.6.5. Middle East & Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.6.6. Middle East & Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.7. Pharmacovigilance Market - Saudi Arabia
      • 11.6.7.1. Saudi Arabia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.7.2. Saudi Arabia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.7.3. Saudi Arabia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.7.4. Saudi Arabia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.7.5. Saudi Arabia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.7.6. Saudi Arabia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.8. Pharmacovigilance Market - UAE
      • 11.6.8.1. UAE: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.8.2. UAE.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.8.3. UAE: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.8.4. UAE: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.8.5. UAE: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.8.6. UAE: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.9. Pharmacovigilance Market - Israel
      • 11.6.9.1. Israel: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.9.2. Israel.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.9.3. Israel: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.9.4. Israel: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.9.5. Israel: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.9.6. Israel: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.6.10. Pharmacovigilance Market - South Africa
      • 11.6.10.1. South Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.6.10.2. South Africa.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.6.10.3. South Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.6.10.4. South Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.6.10.5. South Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.6.10.6. South Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.7. Pharmacovigilance Market - Latin America
    • 11.7.1. Latin America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.7.2. Latin America.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.7.3. Latin America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.7.4. Latin America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.7.5. Latin America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.7.6. Latin America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.7. Pharmacovigilance Market - Mexico
      • 11.7.7.1. Mexico: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.7.2. Mexico.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.7.3. Mexico: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.7.4. Mexico: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.7.5. Mexico: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.7.6. Mexico: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.8. Pharmacovigilance Market - Brazil
      • 11.7.8.1. Brazil: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.8.2. Brazil.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.8.3. Brazil: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.8.4. Brazil: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.8.5. Brazil: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.8.6. Brazil: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
    • 11.7.9. Pharmacovigilance Market - Argentina
      • 11.7.9.1. Argentina: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
      • 11.7.9.2. Argentina.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
      • 11.7.9.3. Argentina: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
      • 11.7.9.4. Argentina: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
      • 11.7.9.5. Argentina: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 11.7.9.6. Argentina: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)

12. Competitive Landscape

  • 12.1. Expansion and Acquisition Analysis
    • 12.1.1. Expansion
    • 12.1.2. Acquisitions
  • 12.2. Partnerships/Collaborations/Agreements/Exhibitions

13. Company Profiles

  • 13.1. Accenture
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Benchmarking
    • 13.1.4. Recent Development
  • 13.2. ArisGlobal
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Benchmarking
    • 13.2.4. Recent Development
  • 13.3. BioClinica, Inc
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Benchmarking
    • 13.3.4. Recent Development
  • 13.4. Capgemini
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Benchmarking
    • 13.4.4. Recent Development
  • 13.5. Clinquest Group B.V. (Linical Americas)
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Benchmarking
    • 13.5.4. Recent Development
  • 13.6. Cognizant
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Benchmarking
    • 13.6.4. Recent Development
  • 13.7. FMD K&L
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Benchmarking
    • 13.7.4. Recent Development
  • 13.8. IBM Corporation
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Benchmarking
    • 13.8.4. Recent Development
  • 13.9. ICON Plc.
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Benchmarking
    • 13.9.4. Recent Development
  • 13.10. IQVIA
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Benchmarking
    • 13.10.4. Recent Development
  • 13.11. ITClinical
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Benchmarking
    • 13.11.4. Recent Development
  • 13.12. Laboratory Corporation of America Holdings
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Benchmarking
    • 13.12.4. Recent Development
  • 13.13. Linical Accelovance
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Benchmarking
    • 13.13.4. Recent Development
  • 13.14. PAREXEL International Corporation
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Benchmarking
    • 13.14.4. Recent Development
  • 13.15. TAKE Solutions
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Benchmarking
    • 13.15.4. Recent Development
  • 13.16. United BioSource Corporation
    • 13.16.1. Company Overview
    • 13.16.2. Financial Performance
    • 13.16.3. Product Benchmarking
    • 13.16.4. Recent Development
  • 13.17. Wipro Limited
    • 13.17.1. Company Overview
    • 13.17.2. Financial Performance
    • 13.17.3. Product Benchmarking
    • 13.17.4. Recent Development

List of Tables

  • Table 1 Global Pharmacovigilance Market, by Service Provider, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Pharmacovigilance Market, by Process Flow, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Pharmacovigilance Market, by Product Life Cycle, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Pharmacovigilance Market, by Type, by Region, 2019-2032 (USD Billion)
  • Table 5 Global Pharmacovigilance Market, by Therapeutic Area, by Region, 2019-2032 (USD Billion)
  • Table 6 Global Pharmacovigilance Market, by End-Use, by Region, 2019-2032 (USD Billion)